Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma.
Brief Summary: This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic RCC. Approximately 160 eligible patients will be stratified based on the ECOG performance status (0 vs. 1) and number of metastatic sites of disease (0 and 1 vs. \>=2). The study consists of two treatment periods of 10 weeks with a 2-week wash-out period between the two treatment periods. Patients will receive pazopanib and sunitinib treatment sequentially in a double-blinded fashion. The primary objective of the study is to assess how the tolerability and safety differences between pazopanib and sunitinib translate into patient preference, defined by the patient's stated preference for which drug they may prefer to continue treatment with at end of study. The secondary objectives are to evaluate the reason for patient preference as assessed by a patient preference questionnaire; to evaluate fatigue as assessed by FACIT-Fatigue and quality of life as assessed by EuroQoL EQ-5D; to evaluate dose modifications and time to dose modification; and to evaluate safety.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
B: Arm Label: Sorafenib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib+Pazopanib | Arm Label: Pazopanib followed by Sorafenib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib+Sorafenib | Intervention Type: DRUG; Name: Sorafenib+Pazopanib; Assigned to Arm(s): Sorafenib followed by pazopanib | Intervention Type: DRUG; Name: Pazopanib+Sorafenib; Assigned to Arm(s): Pazopanib followed by Sorafenib
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
D: Arm Label: pazopanib followed by sunitinib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Arm Label: sunitinib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib

Answer: D